HPV (Human Papillomavirus): Vaccine, Symptoms, Testing, and Men's Health

What Is HPV?

Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the world.

There are more than 40 types of HPV capable of infecting:

• Male and female genital organs
• The mouth
• The throat

In most cases, HPV infection is completely asymptomatic; the majority of infected people never know they carry the virus. In others, however, it can lead to serious health consequences, including cancer.

HPV is distinct from both herpes simplex virus and HIV (the virus that causes AIDS). While all three can be transmitted sexually, they affect different body systems and carry different health risks.

It is estimated that more than 50% of sexually active people will contract at least one HPV infection during their lifetime, with the highest incidence in females up to the age of 25.

In most cases, HPV causes no lasting harm. However:

• Some strains cause genital warts (condylomata acuminata)
• Certain high-risk strains can lead to cancer, including:
  • Cervical cancer (most commonly associated)
  • Anal cancer
  • Oral cancer and throat cancer (from oro-genital contact)
  • Vaginal cancer
  • Penile cancer

What Happens After Infection?

The outcome of an HPV infection depends largely on the immune response of the infected individual and can follow three distinct paths:

1. Regression: The immune system eliminates the virus (most common outcome)
2. Persistence: The virus remains in the body without causing immediate harm, but may do so over time
3. Progression: The infection leads to cellular changes that can become precancerous or cancerous

The majority of high-risk HPV infections resolve spontaneously within 1 to 2 years without causing complications. However, when the infection persists, it can trigger cellular changes that develop over years into precancerous lesions and, eventually, malignancy.

Cervical cancer ranks as the fourth most common cancer in women worldwide. Although HPV infection rates remain high, cervical cancer itself occurs relatively infrequently. This is largely due to effective screening programs, such as the Pap test and HPV test, as well as the availability of a protective vaccine.

The consistent and correct use of latex condoms substantially reduces the risk of HPV transmission, though it does not completely eliminate it. An effective HPV vaccine is now available and provides strong protection against the most dangerous strains.

How Common Is HPV?

The scale of HPV prevalence globally is remarkable:

• In the United States, approximately 20 million people are currently infected (about 6% of the population), with roughly 6 million new infections every year
• Approximately half of all sexually active adults will contract HPV at least once in their lifetime
• About 1% of sexually active U.S. adults have had genital warts at some point in their lives

HPV-related cancers per year in the U.S. (approximate figures):

Important note: HPV is responsible only for a subset of head and neck cancers; other forms are predominantly linked to tobacco and alcohol use.

Recurrent respiratory papillomatosis, caused by HPV transmitted from mother to child, is rare. In the U.S., there are fewer than 2,000 new pediatric cases each year.

---

Why Is HPV Dangerous?

HPV infects the cells of the mucous membranes it targets, causing cellular abnormalities. In most cases, these changes are microscopic and invisible to the naked eye.

In the vast majority of individuals, the immune system successfully neutralizes HPV and the infected cells return to normal. However, when the immune system fails to overcome the infection, the virus can cause two types of visible, clinically significant changes:

1. Genital warts are benign but distressing growths caused by low-risk HPV strains, mainly types 6 and 11
2. Cancer, particularly cases driven by high-risk HPV strains (primarily types 16 and 18, which together cause about 70% of cervical cancers), remains a significant health concern

It is important to understand that the HPV strains responsible for genital warts differ from those that cause cancer. Having one type does not mean you will develop the other. However, co-infection with multiple HPV types is possible.

• Genital warts may appear weeks to months after infection.
• Cancer typically takes years to decades to develop from persistent HPV infection. This is why regular screening is so valuable: it can detect precancerous changes before they progress.

---

Transmission: How Is HPV Contracted?

HPV spreads through direct sexual contact, primarily during vaginal and anal intercourse. It can also be transmitted during oral sex or even through non-penetrative genital skin-to-skin contact. Transmission can occur between heterosexual and same-sex partners, even when the infected partner has no visible symptoms.

Key transmission facts:

• Condoms reduce but do not eliminate risk: Because HPV can infect skin and mucosal surfaces not covered by a condom, protection is partial. Transmission can occur even with consistent condom use.
• Incomplete intercourse can transmit HPV: Penetration is not necessary; genital contact alone is sufficient for transmission.
• HPV can remain active for years: A new HPV diagnosis does not necessarily reflect the current sexual relationship. The virus can stay dormant for a long time before being detected.
• Most infected people don’t know it: The majority of HPV carriers are completely unaware of their infection and may unknowingly transmit it to partners.
• Multiple HPV types can co-exist: It is possible to be infected with more than one HPV strain simultaneously.

Primary Risk Factors for Acquisition

• Young age (especially adolescents and young adults)
• Early age at first sexual intercourse
• Multiple sexual partners or casual sexual contacts

HPV During Pregnancy

The risk of mother-to-child HPV transmission during pregnancy or delivery is considered limited. In general, HPV infection in the mother does not pose specific risks to fetal development. However, in very rare cases, a mother with genital warts may pass the virus to her newborn during vaginal delivery. This can result in recurrent respiratory papillomatosis in the child, a rare but serious condition where warts grow in the throat and airways.

Any treatment for HPV-related lesions during pregnancy is generally deferred until after delivery unless there is an urgent clinical need.

---

Symptoms

The vast majority of people infected with HPV experience no symptoms and no associated health problems. In approximately 80% of cases, the immune system clears the virus naturally within two years without the person ever knowing they were infected.

In some individuals, however, specific HPV strains can cause:

• Genital warts (condylomata acuminata), which affect both men and women.
• Warts in the throat (recurrent respiratory papillomatosis): a rare condition.
• Cervical cancer and other HPV-related cancers, the most serious consequence of infection, are driven by high-risk strains.

Crucially, HPV strains that cause genital warts are different from those that cause cancer. After infection, it is not possible to predict whether an individual will develop cancer or other health problems based on HPV positivity alone.

How Do HPV-Related Conditions Manifest?

Genital Warts (Condylomata Acuminata)

Genital warts are caused by low-risk HPV types (primarily 6 and 11) and typically present as:

• Small, flesh-colored or pink bumps in the genital area
• Single lesions or clusters of wart-like growths (sometimes described as “cauliflower-shaped”)
• Flat or raised; small or large
• Located on the penis, scrotum, vulva, vagina, cervix, anus, or surrounding skin

Warts may appear weeks to months after sexual contact with an infected partner, even if the partner shows no visible symptoms. Without treatment, they may disappear spontaneously, remain unchanged, or increase in size and number. Genital warts do not transform into cancer.

Cervical Cancer

Cervical cancer, caused by high-risk HPV strains (especially 16 and 18), is typically asymptomatic in its early stages. This is why regular screening is so important. When symptoms do appear (abnormal bleeding, pelvic pain, discharge), the cancer may already be in an advanced stage.

Other HPV-Related Cancers

Cancers of the vulva, vagina, penis, anus, tongue, tonsils, and throat caused by HPV also tend to remain asymptomatic until advanced, making awareness and targeted screening in high-risk groups important.

Recurrent Respiratory Papillomatosis

This rare condition causes warts to grow in the larynx and airways. It can lead to hoarseness and breathing difficulties, and may require repeated surgical interventions to manage.

---

Diagnosis and Screening

The primary goal of HPV diagnosis and screening is to detect precancerous lesions early. This allows treatment to begin before they progress to invasive cancer, when it is most effective. In most countries, well-defined screening protocols exist, particularly for cervical cancer in women.

Female Screening

Women’s cervical cancer screening uses two complementary approaches:

1. HPV DNA Test (Primary Screening)

The HPV DNA test is currently the preferred screening test for women over 30–35 years of age. It directly detects the presence of high-risk HPV strains’ genetic material (DNA) in cells collected from the cervix. Key facts:

• Performed every 5 years if negative.
• More sensitive than the Pap test for identifying early risk of precancerous lesions.
• A positive HPV test does not mean cancer is present. Instead, it indicates that a potentially cancer-causing strain is present and warrants further evaluation.

2. Pap Test (Cytology)

The Pap test examines cells collected from the cervix under a microscope for abnormal changes. It remains:

• The primary screening tool for women aged 25 to 29–34 years (every 3 years)
• Used as a triage tool in older women when the HPV test is positive. This helps assess whether the virus has already caused visible cellular changes.

3. Colposcopy and Biopsy

If screening tests are positive or show cytological abnormalities, the next step is colposcopy:

• A specialized microscope is used to examine the cervix in detail, often after applying acetic acid solution to highlight abnormal tissue
• If suspicious areas are identified, a biopsy (small tissue sample) is taken for histological analysis to classify the lesion (e.g., low-grade squamous intraepithelial lesion, L-SIL/CIN 1; or high-grade, H-SIL/CIN 2-3)

Diagnosis in Men and Other Sites

There are currently no validated mass screening programs for HPV in men or for oral/anal HPV infections.

Clinical Examination

Diagnosis in men is primarily based on visual inspection during a medical visit (dermatologist, andrologist, or urologist). Genital warts are clinically recognized.

Peniscopy

A colposcope can be used to examine the penile skin for subclinical HPV lesions not visible to the naked eye. While useful in specialized contexts, it is not recommended as a routine screening tool.

Anal and Oropharyngeal Assessment

In high-risk individuals (e.g., HIV-positive patients, men who have sex with men, or partners of people with confirmed HPV-related lesions), a physician may consider:

• Anal Pap test: to detect precancerous anal lesions
• Detailed oral cavity examination

These are not yet part of standardized national screening guidelines for the general population, but are increasingly used in high-risk clinical settings.

---

Treatment

It is critical to clarify that there is currently no medication that eliminates HPV from the body. The immune system is responsible for clearing the virus naturally in most cases. Medical treatment focuses on managing the clinical manifestations of HPV infection, such as genital warts and precancerous lesions, while also preven ting their progression to cancer.

Treatment of Genital Warts (Condyloma)

If genital warts cause physical discomfort or psychological distress, a physician can offer several treatment options:

Topical (home-applied) therapies:

• Imiquimod cream: Stimulates the local immune response to fight the virus. Applied by the patient at home under medical supervision.
• Podophyllotoxin solution/cream: Directly destroys wart tissue. Applied by the patient, typically in cycles.
• Sinecatechins (green tea extract): A botanical preparation that has been shown to be effective against external genital warts.

In-office procedures:

• Cryotherapy: Application of liquid nitrogen to freeze and destroy wart tissue. This is a fast and widely available option
• Electrocauterization: Electrical current used to burn off warts
• Laser therapy: Particularly useful for extensive or recurrent lesions
• Surgical excision: Traditional removal under local anesthesia

The choice of treatment depends on the number, size, and location of warts, as well as patient preference. Recurrence after treatment is possible because the underlying virus may persist in surrounding tissue.

Treatment of Cervical Precancerous Lesions

When screening reveals cellular abnormalities (cervical dysplasia), treatment aims to remove the abnormal tissue while preserving the cervix:

LLETZ / LEEP (Large Loop Excision of the Transformation Zone): The most common procedure. A wire loop with an electrical current is used to excise the abnormal cervical tissue. It is rapid, effective, performed under local anesthesia, and provides a tissue specimen for histological analysis.

Cone Biopsy (Conization): Removal of a cone-shaped section of the cervix. Reserved for more complex cases, larger lesions, or situations requiring more comprehensive histological assessment.

Watchful Waiting (Active Surveillance): For low-grade lesions (CIN 1 / L-SIL), which have a high probability of resolving spontaneously (estimated at 60–90% over 2 years), close monitoring with repeat testing every 6–12 months is often preferred over immediate intervention. This approach avoids potential procedural risks (including effects on future fertility and preterm birth risk) while maintaining safety through regular follow-up.

Lifestyle and Immune System Support

While there is no specific “anti-HPV diet”, lifestyle choices have a clinically meaningful impact on the immune system’s ability to clear HPV:

• Quit smoking: Tobacco smoking is one of the most important co-factors that impairs the immune clearance of HPV, increasing the risk of persistent infection and progression to cervical cancer. Smoking cessation is a priority recommendation for HPV-positive patients.
• Balanced nutrition: A diet rich in fruits, vegetables, and micronutrients (particularly folate, vitamins C and E, and beta-carotene) supports immune function.
• Stress management and sleep: Chronic stress and sleep deprivation impair immune surveillance. Addressing these factors may support natural viral clearance.
• Consistent condom use: While not fully protective against HPV, condom use reduces the viral load (exposure concentration) and may accelerate clearance of the infection in established sexual partnerships.

---

HPV Vaccine

The HPV vaccine is the most powerful tool available for preventing HPV infection and its associated diseases. Current vaccine formulations protect both men and women against the most dangerous HPV strains.

Vaccines are administered as a 2- to 3-dose series (depending on age at first dose), and it is important to complete the full series for maximum protection. Vaccines are most effective when given before any sexual activity begins. Since this means administering them before potential exposure to the virus, national immunization programs target pre-adolescent children.

Available Vaccines

For girls and women: Two vaccines are commercially available:

• Cervarix® (bivalent): Protects against HPV types 16 and 18, which are responsible for approximately 70% of cervical cancers.
• Gardasil® (quadrivalent or 9-valent): Protects against HPV types 16 and 18 (cancer) as well as types 6 and 11 (genital warts). The 9-valent Gardasil 9 also protects against five additional high-risk types (31, 33, 45, 52, 58), covering approximately 90% of cervical cancers.

Both vaccines are recommended for girls starting at age 11–12, and for women up to age 26 who were not previously vaccinated or did not complete the series. Vaccination can begin as early as age 9.

For boys and men:

• Gardasil® protects men against genital warts and HPV-related cancers. It is recommended for males aged 9 to 26. The Advisory Committee on Immunization Practices (ACIP) also recommends consideration of vaccination in males up to age 45 after shared decision-making with a healthcare provider.

Note: If possible, use the same brand of vaccine throughout the complete vaccination series.

Important Vaccination Considerations

• Vaccinated individuals still need cervical screening: The vaccine does not protect against all HPV types that can cause cervical cancer. Even vaccinated women must continue regular Pap tests and HPV DNA tests according to current guidelines.
• Vaccination after HPV exposure: Vaccination is still recommended even if a person has already been exposed to HPV (or has had genital warts or an abnormal Pap test), as the vaccine protects against strains not yet contracted.
• The vaccine is not a treatment: It does not eliminate an existing HPV infection and does not treat existing lesions or diseases.

Additional Protective Measures

Since the HPV vaccine does not protect against all sexually transmitted infections, the following complementary precautions remain important:

• Consistent and correct condom use during all sexual activity reduces HPV transmission risk. However, condoms are not 100% effective because HPV can infect areas not covered by the condom.
• Limiting the number of sexual partners and choosing partners who have had fewer previous partners can reduce cumulative exposure risk.
• The only 100% certain way to prevent HPV is sexual abstinence. However, this is not a realistic or appropriate recommendation for most adults.

Prevention of Specific HPV-Related Conditions

Genital Warts

Gardasil® protects both men and women against the HPV types most commonly responsible for genital warts (types 6 and 11).

Cervical Cancer

Both Cervarix® and Gardasil® provide strong protection against the HPV strains responsible for most cervical cancers. Regular cervical screening remains essential even in vaccinated women, as no vaccine covers 100% of cancer-causing strains.

Anal and Penile Cancer

No validated screening test is currently approved for general population screening. However, annual anal Pap testing is recommended by some experts for gay and bisexual men and HIV-positive individuals, given the significantly higher incidence of anal cancer in these groups.

Head and Neck Cancers

No approved early detection test exists. Suspicious symptoms (persistent sore throat, hoarseness, difficulty swallowing, or a lump in the neck) should prompt specialist evaluation.

Recurrent Respiratory Papillomatosis

Cesarean delivery is not routinely recommended solely to prevent neonatal HPV transmission for women with genital warts, as evidence does not clearly support its effectiveness in preventing respiratory papillomatosis in the child.

---

Frequently Asked Questions

What is HPV (human papillomavirus)?

HPV is a sexually transmitted virus that primarily infects the genitals (both male and female) and can also affect the mucous membranes of the mouth and throat. It has gained significant attention because certain high-risk strains can cause cancer. This is especially true for cervical cancer, which affects both men and women.

What are condylomata (genital warts)?

Condylomata (genital warts) are visible growths on the skin and mucous membranes of the genital area, caused by infection with low-risk HPV types (principally 6 and 11). It is important to note that the HPV strains that cause genital warts are not the same strains responsible for cancer.

How is HPV treated?

In most cases, the immune system clears the infection on its own within 1 to 2 years, without treatment or symptoms. For those who do develop problems:

• Genital warts can be removed using topical medications or in-office procedures (cryotherapy, laser, electrocauterization)
• Precancerous cervical lesions are treated by surgical removal of abnormal tissue (LEEP/LLETZ or cone biopsy)
• Active surveillance is appropriate for low-grade lesions that are likely to resolve spontaneously

There is no drug that permanently eliminates the virus itself.

How is HPV transmitted?

HPV spreads through sexual contact. This includes vaginal, anal, and oral sex, along with genital skin-to-skin contact even without penetration. Condoms and the HPV vaccine are the most effective protective measures.

How is HPV tested for in men?

In men, visible genital warts are diagnosed by clinical inspection during a medical visit. However, diagnosing silent HPV infection in men (without visible warts) is significantly more challenging. There is no validated, standardized HPV screening test approved for routine use in men in most countries.

My partner has HPV. What should I do?

It is important that your partner be evaluated and monitored by a healthcare provider. If not already vaccinated, consider HPV vaccination. Use condoms consistently to reduce, though not eliminate, transmission risk. Be aware that you may already have been exposed.

If I have HPV, can I have sex?

Yes. Having HPV does not mean you must abstain from sexual activity. However, using condoms during every sexual encounter is strongly recommended to reduce the risk of transmission to partners. Discuss the situation openly with your healthcare provider and ideally with your partner.

How long after exposure do HPV symptoms appear?

Many people never develop any symptoms and the virus may be cleared by the immune system without the person ever knowing they were infected. In those who do develop symptoms, genital warts may appear weeks to months after exposure, while HPV-related cancers may take years or even decades to develop from the time of initial infection.

Can someone be a healthy HPV carrier?

Yes. It is very common to carry HPV without developing any symptoms or health problems. However, carriers can still transmit the virus to sexual partners even in the absence of visible lesions.

Besides condoms, what else helps protect against HPV?

The HPV vaccine is the most effective protective measure available after abstinence. It significantly reduces the risk of infection with the most dangerous and common HPV strains, and is most effective when given before sexual activity begins.

I had a negative Pap test in the past but now test HPV positive. Is that possible?

Yes. HPV can remain dormant in the body for many years. A previously negative Pap test reflects the absence of detectable cell changes at that moment in time, but the virus may have been acquired before the test without producing visible cellular abnormalities. This is a common and completely normal scenario.

What are the risks if I test positive for HPV?

Testing positive for HPV means a cancer-associated virus is present, but it does not mean you have cancer or will develop cancer. The vast majority of HPV infections resolve without causing lasting harm. What is required is appropriate monitoring, such as regular Pap tests, HPV DNA testing, and colposcopy when indicated, to detect any cellular changes early when they are most treatable.

---

Sources and Bibliography

• Istituto Superiore di Sanità (ISS). Epidemiologia HPV in Italia. Available from: https://www.epicentro.iss.it/problemi/hpv/EpidITA.asp

• Medina Palacios KY, et al. Human Papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain. PubMed Central. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696457/

• MSD Manuals Professional. Recurrent Respiratory Papillomatosis. Available from: https://www.msdmanuals.com/professional/pediatrics/miscellaneous-ear-nose-and-throat-disorders-in-children/recurrent-respiratory-papillomatosis

• Centers for Disease Control and Prevention (CDC). Genital HPV Infection: Basic Fact Sheet Available from: https://www.cdc.gov/sti/about/about-genital-hpv-infection.html

• National Cancer Institute. HPV and Cancer. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet

• World Health Organization (WHO). Human papillomavirus (HPV) and cervical cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cervical-cancer

• American Cancer Society. The HPV Vaccine: What You Need to Know. Available from: https://www.cancer.org/cancer/cervical-cancer/prevention-and-early-detection/hpv-vaccines.html

• Garland SM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943.